Enhertu improved PFS in HER2-low and ultralow
Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial AstraZeneca and Daiichi Sankyo’s Enhertu also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2-ultralow expressionPositive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful